Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

Core Insights - Starbucks appointed Brian Niccol as the new CEO to revitalize sales growth, particularly in the U.S. and China, which are its largest markets [1] - Prior to Niccol's appointment, Starbucks experienced a decline in same-store sales, with a drop of 7% in the fiscal fourth-quarter of 2024, including declines of 6% in the U.S. and 14% in China [2] Investment Performance - Over the past five years, Starbucks shares have shown volatility, with a price increase of 5.7% and a total return of 17.7% when including dividends, making a $5,000 investment worth approximately $5,285 today, or $5,886 with reinvested dividends [3] - In comparison, the S&P 500 index returned over 84% during the same period, indicating that a $5,000 investment in the index would be worth over $9,180, highlighting Starbucks' underperformance relative to the broader market [4] Current Market Conditions - Early in Niccol's tenure, fiscal first-quarter same-store sales in the U.S. fell by 4%, while China saw a 6% decline [5] - The current valuation of Starbucks stock, with a price-to-earnings (P/E) ratio of 26, is not considered a discount compared to the S&P 500, which has the same P/E ratio, although Starbucks' P/E is slightly lower than its 10-year median of 30 [4][5]

Group 1: Viking Therapeutics - Viking Therapeutics is a clinical-stage biotech company focused on developing medicines for metabolic and endocrine disorders, with a notable candidate VK2735 for weight management therapy [2][6] - The market for anti-obesity drugs is rapidly growing, and Viking's VK2735 has shown strong mid-stage results compared to competitors [3][4] - The company is also developing VK2809 for metabolic dysfunction-associated steatohepatitis and VK0214 for X-linked adrenoleukodystrophy, showcasing a diverse pipeline [4][5] - Viking is exploring next-generation weight loss medicines that mimic the action of hormones amylin and calcitonin, indicating a proactive approach to innovation [5][6] - Despite recent struggles, clinical and regulatory progress could lead to substantial gains, making it an attractive investment for those willing to accept volatility [6] Group 2: PayPal - PayPal's shares have declined due to disappointing fourth-quarter results, particularly from its Braintree payment processing platform [7][8] - The company has strategically chosen to abandon unprofitable volume, which may lead to lower short-term sales but higher future profits and margins [8] - PayPal has made significant changes to its business, including the development of an advertising business that could enhance revenue by linking active accounts with businesses [9][8] - With 434 million active accounts at the end of 2024, PayPal maintains a strong brand presence and a vast network of businesses, enhancing its attractiveness to consumers [9][10] - The company's platform benefits from a network effect, which strengthens its competitive position in the fintech industry, suggesting long-term growth potential [10][11]

Amid the volatility of energy commodity prices, some companies maintain stable performance in their upstream and downstream operations. One of these is Chevron Corporation (NYSE: CVX ). As a dominant figure for over a century, it Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CVX over the next 72 hours. I wr ...

Group 1 - The Hershey Company (HSY) is recognized for its strong brand portfolio, including Hershey, Reese's, and recent acquisitions like Dot's Pretzels, SkinnyPop, and LesserEvil [1] Group 2 - The company is positioned in the consumer goods sector, particularly in the confectionery market, which is characterized by strong brand loyalty and consistent demand [1]

Group 1 - Seeking Alpha welcomes Trading Key as a new contributing analyst, providing a platform for investment ideas and analysis [1] - Trading Key is a professional financial website with a team of analysts and editors from top universities, specializing in macroeconomics, commodities, currencies, and the U.S. stock market [2] Group 2 - The article emphasizes that the analysts have no current stock or derivative positions in the companies mentioned, ensuring unbiased opinions [3] - Seeking Alpha clarifies that past performance does not guarantee future results and that the views expressed may not reflect the overall stance of the platform [4]

Group 1 - SoFi Technologies (NASDAQ: SOFI) stock has decreased nearly 40% since a 'Strong buy' recommendation in early December, despite strong Q4 2024 earnings [1] - The decline in stock price began in late January due to softer-than-expected guidance following the earnings report [1] Group 2 - The author has a long position in SoFi shares through stock ownership, options, or other derivatives [2] - The article reflects the author's own opinions and is not compensated by any company mentioned [2]

Group 1 - This year has posed significant challenges for tech companies, including Alphabet Inc., which, despite being classified as a Communications Services firm, has seen its stock price decline [1] - The investing group Beyond the Wall Investing offers features such as a fundamentals-based portfolio, weekly analysis on institutional investor insights, and alerts for short-term trade ideas based on technical signals [1]

Core Viewpoint - Wall Street analysts are showing renewed confidence in the healthcare sector, particularly with Gilead Sciences, indicating a potential shift in sentiment and highlighting the sector as a safe haven for investors [1][5]. Gilead Sciences - J.P. Morgan upgraded Gilead Sciences, marking a pivotal endorsement and signaling optimism in the company's valuation and the broader healthcare sector [5]. - Gilead's stock has outperformed the S&P 500 by 27% over the past quarter, trading at 93% of its 52-week high, which has attracted institutional interest [4][7]. - Analysts forecast a 12-month price target of $105.12 for Gilead, with a potential upside to $130, representing a 16.1% increase from current levels [4][7]. Pfizer Inc. - Pfizer is viewed as a value-based, defensive opportunity, trading at 80% of its 52-week high, with a 12-month price forecast of $31.92, indicating a 30.17% upside [9][10]. - Analysts project a significant increase in Pfizer's third-quarter EPS to $1.00, a 51.5% rise from the current 66-cent EPS, supporting the bullish outlook [10]. - Pfizer offers a 6.8% annual dividend yield, providing stability and income in a volatile market [11]. Hims & Hers Health Inc. - Hims & Hers is positioned as a contrarian growth play, with a 12-month price forecast of $37.31, suggesting a 20.20% upside [12]. - The stock has attracted $739 million of institutional capital over the past quarter, indicating growing interest despite trading at only 38% of its 52-week high [13]. - Hims & Hers trades at a high P/E ratio of 66.1, reflecting market expectations for future outperformance in the digital healthcare space [14].

Palantir's ( PLTR ) valuation premium seemed too high when I shared my 'Hold' recommendation . Nevertheless, PLTR is 6% more expensive now compared to December 23, 2024. The latest quarterly performance was nothing but stellar, which further boosted the market's confidence Coming from an IT background, I have dived into the U.S. stock market seven years ago by managing portfolio of my family. Starting managing real money has been challenging for the first time, but long hours of mastering fundamental analys ...